What type of study is this?

This is a In Vitro Study study.

What question did this study set out to answer?

This research evaluates the in vitro activity of Corallopyronin A against various Staphylococcus strains.

March 14, 2026Infection0 citationsOpen Access

View Full Paper

Corallopyronin A exhibits potent activity against staphylococci including MRSA and isolates from prosthetic infections

JKJesenko Karačić MGMiriam Grosse KPKenneth Pfarr

Key Points

This research evaluates the in vitro activity of Corallopyronin A against various Staphylococcus strains.
Evaluated 116 staphylococcal strains using minimum inhibitory concentration (MIC) testing.
Determined minimum bactericidal concentrations (MBCs) for 70 strains.
Conducted time-kill assays on 5 S. aureus strains using 4 × MIC of CorA.
Performed checkerboard assays with 11 antibiotics for potential interactions.
CorA exhibited MIC values between 0.125 to 2 mg/L with a MIC90 of 0.5 mg/L for S. aureus.
71% of CNS isolates and 34% of S. aureus strains showed bactericidal activity.
Time-kill assays indicated a 1.5-3 log 10 CFU/mL reduction in viable counts within 24 hours.
Additive interactions were found with glycopeptides like dalbavancin.

Abstract

Abstract Purpose This study evaluates the in vitro antimicrobial activity of Corallopyronin A (CorA) against a diverse collection of Staphylococcus aureus and coagulase-negative staphylococci (CNS), comprising both laboratory strains and clinical isolates. The dataset includes methicillin-resistant and methicillin-susceptible strains, as well as small colony variants (SCVs), to assess its therapeutic potential in staphylococcal infections. Methods A total of 116 staphylococcal strains, comprising clinical isolates and laboratory strains, were subjected to minimum inhibitory concentration (MIC) testing. Minimum bactericidal concentrations (MBCs) were determined for a subset of 70 strains. Time-kill assays were conducted for five S. aureus strains using 4 × MIC of CorA. Additionally, checkerboard assays were performed with 11 antibiotics to evaluate potential additive or synergistic interactions. Results CorA demonstrated potent antimicrobial activity with MIC values ranging from 0.125 to 2 mg/L. The MIC 90 was 0.5 mg/L for S. aureus and 1 mg/L for CNS. Methicillin-resistant strains exhibited significantly higher susceptibility than methicillin-sensitive strains. Time-kill assays revealed a reduction of 1.5-3 log 10 CFU/mL in viable counts within 24 h. Minimum bactericidal concentration testing showed bactericidal activity in a subset of strains, occurring in 71% of CNS isolates and 34% of S. aureus strains, while the remaining S. aureus and CNS isolates displayed a bacteriostatic response. Checkerboard assays indicated additive interactions with glycopeptides, including dalbavancin and oritavancin. Conclusions CorA shows strong in vitro activity against a broad range of staphylococcal strains, particularly methicillin-resistant isolates. Its additive effects with clinically relevant antibiotics further support its potential in combination therapy for the treatment of resistant staphylococcal infections.

AI से पूछें

Bookmark

View Full Paper

AI से पूछें

Bookmark

View Full Paper

Corallopyronin A exhibits potent activity against staphylococci including MRSA and isolates from prosthetic infections

Key Points

Abstract

Cite This Study

Also Consider

Also Consider